Each trial will enroll at least 1,000 participants who have been diagnosed with these illnesses and diseases.Many infectious diseases are increasingly difficult to treat because bacteria and other microbes have developed resistance to commonly used antimicrobial drugs, says NIAID Director Anthony S. Fauci, M.D. Research to preserve the effectiveness of licensed antibiotics is a critical priorit